Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 4.12 Billion | USD 17.38 Billion | 17.4% | 2024 |
The global gene panel market size was worth around USD 4.12 Billion in 2024 and is predicted to grow to around USD 17.38 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 17.4% between 2025 and 2034. The report analyzes the global gene panel market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the gene panel industry.
A gene panel is a diagnostic testing tool for analyzing the possibility of multiple genes for cancer-associated mutations. They are also used for treatments of diseases such as cancer, syndrome-specific disorders, and any random infections. A gene panel test is considered to be the most reliable test for diagnostic purposes than any BRCA1/2 genetics test. They diagnose the possibility of breast cancer and also identify patients at risk.
They are also capable of detecting and capturing all relevant information regarding a disease including genome sequencing in the genome. Targeted gene paneling testing has been used for genetic disorders such as hearing impairment or eye defects that are caused due to mutations.
Untargeted disease gene panel testing includes testing multiple genes to identify any intellectual or inherent disabilities which are not generally available to the family. Women and men can have mutations in BRCA1 or BRCA2 genes and gene panels analyze the risk of developing any type of cancer rights from fallopian tubes, ovaries, breasts, and also prostate in men.
These tests also include multiple litigation-dependent probe amplification signals and QPCR reactions. This makes it feasible not only for diagnostic purposes but also for predictive and prevention treatments which avert a disease even before the person is affected.
An increasing number of cancer cases and technological advancements in research for cancer therapies induce market growth
Rapidly increasing cancer cases across the world and the influx of chronic diseases in the geriatric population drive growth for the gene panel market. There are a number of initiatives by different companies globally and the benefits of gene panels to fight cancer boost market growth as well.
One of the other contributing factors to the growth of the market is the increasing focus on prenatal diagnosis and predictions of disorders in people prior to their infection. There has also been a great demand for genetic testing coupled with technological advancements like generation sequencing systems which propel market growth massively.
Growing demand for advanced medical testing along with options for personalized medicines in clinical diagnosis also promise market growth. Gene panel’s extensive leverage in the diagnosis of congenital diseases and pharmacogenetics also impel growth in the global market.
Many pharmaceutical companies are focusing on the research of targeted therapies for treating cancer. These companies use gene panels widely thereby fueling the market growth. Genetic mutation disorders have become common these days amongst the geriatric population which supports the gene panel market exquisitely.
Increasing security concerns on genetic data and lack of accuracy hinder the market growth
Factors that hinder market growth are the increasing security concerns about the security of the data and lack of preciseness in the outcome. There is also a general standardization of results in diagnostic tests which restricts the leverage of gene panels. The awareness about gene panels and their benefits is lesser in developing countries and there is also a low adoption of advanced technologies here which impedes the growth of the global gene panel market.
Technological advancements in gene panels testing provide lucrative opportunities for the market
Leading companies have come up with new plans for effective gene panels with improved technological advancements that provide opportunities going ahead. There has also been an increase in the prevalence of cancer in recent times along with age-related disorders which seems to provide opportunities for market expansion. Government initiative in population sequencing and modernization of healthcare techniques will provide excellent growth to the market. The continuing research and developments pertaining to gene sequencing could offer significant opportunities for the development of the market.
Stringent rules for the functioning of pharmaceutical companies pose a challenge to the market
Pharmaceutical companies use gene panels extensively for various research and development programs including personalized medical testing purposes to diagnose and treat cancers. However, government regulations regarding the operations of these pharmaceutical companies along with the restrictions on their testing methods implemented by the government pose a challenge to the market growth of the gene panel market.
Increase in the cost of testing due to inappropriate results challenges market growth
The accuracy of the gene panel test is slightly lower and needs repetitive testing to clarify results. Hence, the correction of erroneous results happens through iteration which increases the cost of testing. This factor slightly obstructs market growth and also considerably poses a challenge for market growth.
Report Attributes | Report Details |
---|---|
Report Name | Gene Panel Market |
Market Size in 2024 | USD 4.12 Billion |
Market Forecast in 2034 | USD 17.38 Billion |
Growth Rate | CAGR of 17.4% |
Number of Pages | 165 |
Key Companies Covered | Agilent Technologies, Thermo Fisher Scientific, Hoffmann-La Roche Ltd, Qiagen, Illumina Inc., BGI Genomics, Integrated DNA Technologies Inc., Genewiz, Novogene Corporation, Personalis Inc., GATC Biotech AG, ArcherDX Inc., GeneDX, Centogene Ag, Invitae Corporation,, and others. |
Segments Covered | By Product & Service, By Design, By Technique, By Application, By End-User, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2024 |
Forecast Year | 2025 to 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
The global gene panel market is segmented based on Product & Service, Design, Technique, Application, End-User, and region.
Based on Product & Service, the global gene panel market is divided into Test Kits and Testing Services.
On the basis of Design, the global gene panel market is bifurcated into Predesigned Gene Panels and Customized Gene Panels.
By Technique, the global gene panel market is split into Amplicon-Based Approach and Hybridization-Based Approach.
In terms of Application, the global gene panel market is categorized into Cancer Risk Assessment, Diagnosis, and Pharmacogenetics.
By End-User, the global Gene Panel market is divided into Hospitals, Clinics, Research Organizations, and Academic Institutes.
The market in North America contributes the largest share of the global gene panel market due to the rising cases of chronic and infectious diseases here. There has been increasing support from the government for genomics research which increases the demand for gene panels here. The rising focus on research on rare diseases, genetic disorders, and NGS-based applications coupled with technological advancements fuel the regional market growth.
Europe trails as the second-largest market due to the increase in modernized healthcare systems, research & development activities, and the emergence of new effective gene panels in access.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the gene panel market on a global and regional basis.
The global gene panel market is dominated by players like:
The global gene panel market is segmented as follows;
By Product & Service
By Design
By Technique
By Application
By End-User
By Region
FrequentlyAsked Questions
The global gene panel market is expected to grow due to rising demand for precision medicine, increasing applications in cancer diagnostics, and advancements in next-generation sequencing (ngs) technologies.
According to a study, the global gene panel market size was worth around USD 4.12 Billion in 2024 and is expected to reach USD 17.38 Billion by 2034.
The global gene panel market is expected to grow at a CAGR of 17.4% during the forecast period.
North America is expected to dominate the gene panel market over the forecast period.
Leading players in the global gene panel market include Agilent Technologies, Thermo Fisher Scientific, Hoffmann-La Roche Ltd, Qiagen, Illumina Inc., BGI Genomics, Integrated DNA Technologies Inc., Genewiz, Novogene Corporation, Personalis Inc., GATC Biotech AG, ArcherDX Inc., GeneDX, Centogene Ag, Invitae Corporation,, among others.
The report explores crucial aspects of the gene panel market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed